Thomas Harnath1, Alexander Marx2, Philipp Ströbel2, Edwin Bölke1, Reinhart Willers3, Stephan Gripp4. 1. Department of Radiation Oncology, University Hospital at Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. 2. Department of Pathology, Medical Faculty Mannheim University of Heidelberg, Mannheim, Germany. 3. Department of Biostatisitcs, University Hospital Düsseldorf, Duesseldorf, Germany. 4. Department of Radiation Oncology, University Hospital at Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. Electronic address: gripp@uni-duesseldorf.de.
Abstract
INTRODUCTION: To evaluate prognostic factors of thymic epithelial tumors (TETs) with particular reference to histology and the dose-response relationship of adjuvant radiotherapy. METHODS: Retrospective study with central pathological review on patients resected for TET between 1966 and 2004 at a single institution. Prognostic factors were identified using Cox regression analysis. RESULTS: From 93 patients with TET, 33.3% relapsed and 47.3% died. Cause of death was known in 64% and attributed to TET in 25%. Myasthenia gravis was associated with superior disease-free survival (DFS) and overall survival (OS). Tumors smaller than 8.5 cm had a significantly better prognosis. With a median follow-up of 9.8 years actuarial OS at 5, 10, and 20 years were 96%, 92%, and 47% in stage I; 85%, 61%, and 53% in stage II; 72%, 39%, and 15% in stage III and IV. Advanced stage and incomplete resection had a negative impact on DFS and OS. According to histology (WHO type A, AB, B1; favorable; versus WHO type B2, B3; intermediate; versus thymic carcinoma, unfavorable) three prognostic groups were discernible. On multivariate analysis, tumor size, and stage emerged as prognostic factors, but neither histology nor myasthenia. Postoperative radiotherapy was administered in 27 patients (median dose 50.8 Gy). Doses in excess of 50 Gy were associated with significantly improved DFS and OS. CONCLUSIONS: Tumor stage, histology, complete resection, and tumor size had a significant impact on survival. Myasthenia may facilitate early detection and is correlated with superior survival. When postoperative radiotherapy is administered, doses above 50 Gy may improve outcome.
INTRODUCTION: To evaluate prognostic factors of thymic epithelial tumors (TETs) with particular reference to histology and the dose-response relationship of adjuvant radiotherapy. METHODS: Retrospective study with central pathological review on patients resected for TET between 1966 and 2004 at a single institution. Prognostic factors were identified using Cox regression analysis. RESULTS: From 93 patients with TET, 33.3% relapsed and 47.3% died. Cause of death was known in 64% and attributed to TET in 25%. Myasthenia gravis was associated with superior disease-free survival (DFS) and overall survival (OS). Tumors smaller than 8.5 cm had a significantly better prognosis. With a median follow-up of 9.8 years actuarial OS at 5, 10, and 20 years were 96%, 92%, and 47% in stage I; 85%, 61%, and 53% in stage II; 72%, 39%, and 15% in stage III and IV. Advanced stage and incomplete resection had a negative impact on DFS and OS. According to histology (WHO type A, AB, B1; favorable; versus WHO type B2, B3; intermediate; versus thymic carcinoma, unfavorable) three prognostic groups were discernible. On multivariate analysis, tumor size, and stage emerged as prognostic factors, but neither histology nor myasthenia. Postoperative radiotherapy was administered in 27 patients (median dose 50.8 Gy). Doses in excess of 50 Gy were associated with significantly improved DFS and OS. CONCLUSIONS:Tumor stage, histology, complete resection, and tumor size had a significant impact on survival. Myasthenia may facilitate early detection and is correlated with superior survival. When postoperative radiotherapy is administered, doses above 50 Gy may improve outcome.
Authors: Matthias Felix Häfner; Falk Roeder; Florian Sterzing; David Krug; Stefan A Koerber; Jutta Kappes; Hans Hoffmann; Alla Slynko; Jürgen Debus; Marc Bischof Journal: Strahlenther Onkol Date: 2014-08-26 Impact factor: 3.621
Authors: David I Suster; A Craig Mackinnon; Marcello DiStasio; Malay Kumar Basu; German Pihan; Saul Suster Journal: Mod Pathol Date: 2022-02-10 Impact factor: 8.209
Authors: Jinchun Yan; Qin Liu; Jessica N Moseley; Christina S Baik; Laura Q M Chow; Bernardo H M Goulart; David Zlotnick; Antoni Papanicolau-Sengos; Ian Gallaher; Joy M Knopp; Jing Zeng; Shilpen Patel Journal: Am J Clin Oncol Date: 2016-06 Impact factor: 2.339
Authors: Douglas Z Liou; Divya Ramakrishnan; Natalie S Lui; Joseph B Shrager; Leah M Backhus; Mark F Berry Journal: J Thorac Dis Date: 2020-04 Impact factor: 2.895